Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
20,707
archived clinical trials in
Gastrointestinal

Defibrotide for Patients With Hepatic Veno-occlusive Disease: A Treatment IND Study
Defibrotide for Patients With Hepatic Veno-occlusive Disease: A Treatment IND Study
Status: Enrolling
Updated:  11/2/2017
Providence Sacred Heart Medical Center & Children's Hospital
mi
from
Spokane, WA
Defibrotide for Patients With Hepatic Veno-occlusive Disease: A Treatment IND Study
Defibrotide for Patients With Hepatic Veno-occlusive Disease: A Treatment IND Study
Status: Enrolling
Updated: 11/2/2017
Providence Sacred Heart Medical Center & Children's Hospital
mi
from
Spokane, WA
Click here to add this to my saved trials
Defibrotide for Patients With Hepatic Veno-occlusive Disease: A Treatment IND Study
Defibrotide for Patients With Hepatic Veno-occlusive Disease: A Treatment IND Study
Status: Enrolling
Updated:  11/2/2017
Mary Babb Randolph Cancer Center - West Virginia University Hospital
mi
from
Morgantown, WV
Defibrotide for Patients With Hepatic Veno-occlusive Disease: A Treatment IND Study
Defibrotide for Patients With Hepatic Veno-occlusive Disease: A Treatment IND Study
Status: Enrolling
Updated: 11/2/2017
Mary Babb Randolph Cancer Center - West Virginia University Hospital
mi
from
Morgantown, WV
Click here to add this to my saved trials
Defibrotide for Patients With Hepatic Veno-occlusive Disease: A Treatment IND Study
Defibrotide for Patients With Hepatic Veno-occlusive Disease: A Treatment IND Study
Status: Enrolling
Updated:  11/2/2017
University of Wisconsin, American Family Children's Hospital, Medical School
mi
from
Madison, WI
Defibrotide for Patients With Hepatic Veno-occlusive Disease: A Treatment IND Study
Defibrotide for Patients With Hepatic Veno-occlusive Disease: A Treatment IND Study
Status: Enrolling
Updated: 11/2/2017
University of Wisconsin, American Family Children's Hospital, Medical School
mi
from
Madison, WI
Click here to add this to my saved trials
Defibrotide for Patients With Hepatic Veno-occlusive Disease: A Treatment IND Study
Defibrotide for Patients With Hepatic Veno-occlusive Disease: A Treatment IND Study
Status: Enrolling
Updated:  11/2/2017
Medical College of Wisconsin/ Children's Hospitalof Wisconsin
mi
from
Milwaukee, WI
Defibrotide for Patients With Hepatic Veno-occlusive Disease: A Treatment IND Study
Defibrotide for Patients With Hepatic Veno-occlusive Disease: A Treatment IND Study
Status: Enrolling
Updated: 11/2/2017
Medical College of Wisconsin/ Children's Hospitalof Wisconsin
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Defibrotide for Patients With Hepatic Veno-occlusive Disease: A Treatment IND Study
Defibrotide for Patients With Hepatic Veno-occlusive Disease: A Treatment IND Study
Status: Enrolling
Updated:  11/2/2017
All Children's Hospital Specialty Physicians
mi
from
Saint Petersburg, FL
Defibrotide for Patients With Hepatic Veno-occlusive Disease: A Treatment IND Study
Defibrotide for Patients With Hepatic Veno-occlusive Disease: A Treatment IND Study
Status: Enrolling
Updated: 11/2/2017
All Children's Hospital Specialty Physicians
mi
from
Saint Petersburg, FL
Click here to add this to my saved trials
Defibrotide for Patients With Hepatic Veno-occlusive Disease: A Treatment IND Study
Defibrotide for Patients With Hepatic Veno-occlusive Disease: A Treatment IND Study
Status: Enrolling
Updated:  11/2/2017
Henry Ford Hospital
mi
from
Detroit, MI
Defibrotide for Patients With Hepatic Veno-occlusive Disease: A Treatment IND Study
Defibrotide for Patients With Hepatic Veno-occlusive Disease: A Treatment IND Study
Status: Enrolling
Updated: 11/2/2017
Henry Ford Hospital
mi
from
Detroit, MI
Click here to add this to my saved trials
Defibrotide for Patients With Hepatic Veno-occlusive Disease: A Treatment IND Study
Defibrotide for Patients With Hepatic Veno-occlusive Disease: A Treatment IND Study
Status: Enrolling
Updated:  11/2/2017
Cardinal Glennon Children's Medical Center/St. Louis University Department of Pediatrics
mi
from
Saint Louis, MO
Defibrotide for Patients With Hepatic Veno-occlusive Disease: A Treatment IND Study
Defibrotide for Patients With Hepatic Veno-occlusive Disease: A Treatment IND Study
Status: Enrolling
Updated: 11/2/2017
Cardinal Glennon Children's Medical Center/St. Louis University Department of Pediatrics
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Defibrotide for Patients With Hepatic Veno-occlusive Disease: A Treatment IND Study
Defibrotide for Patients With Hepatic Veno-occlusive Disease: A Treatment IND Study
Status: Enrolling
Updated:  11/2/2017
Washington University/St. Louis Children's Hospital
mi
from
Saint Louis, MO
Defibrotide for Patients With Hepatic Veno-occlusive Disease: A Treatment IND Study
Defibrotide for Patients With Hepatic Veno-occlusive Disease: A Treatment IND Study
Status: Enrolling
Updated: 11/2/2017
Washington University/St. Louis Children's Hospital
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Defibrotide for Patients With Hepatic Veno-occlusive Disease: A Treatment IND Study
Defibrotide for Patients With Hepatic Veno-occlusive Disease: A Treatment IND Study
Status: Enrolling
Updated:  11/2/2017
Presbyterian Hospital
mi
from
Albuquerque, NM
Defibrotide for Patients With Hepatic Veno-occlusive Disease: A Treatment IND Study
Defibrotide for Patients With Hepatic Veno-occlusive Disease: A Treatment IND Study
Status: Enrolling
Updated: 11/2/2017
Presbyterian Hospital
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Defibrotide for Patients With Hepatic Veno-occlusive Disease: A Treatment IND Study
Defibrotide for Patients With Hepatic Veno-occlusive Disease: A Treatment IND Study
Status: Enrolling
Updated:  11/2/2017
Montefiore Medical Center
mi
from
The Bronx, NY
Defibrotide for Patients With Hepatic Veno-occlusive Disease: A Treatment IND Study
Defibrotide for Patients With Hepatic Veno-occlusive Disease: A Treatment IND Study
Status: Enrolling
Updated: 11/2/2017
Montefiore Medical Center
mi
from
The Bronx, NY
Click here to add this to my saved trials
The Effect of Gum Chewing on Postoperative Ileus
The Effect of Gum Chewing on Postoperative Ileus
Status: Enrolling
Updated:  11/2/2017
Brenner Children's Hospital
mi
from
Winston-Salem, NC
The Effect of Gum Chewing on Postoperative Ileus
The Effect of Gum Chewing on Postoperative Ileus
Status: Enrolling
Updated: 11/2/2017
Brenner Children's Hospital
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Wound Healing of Incisional Wounds for Bilateral Hernia Repair
The Effect of a Sodium Bicarbonate and Hydrogen Peroxide Gel on Wound Healing of Incisional Wounds for Bilateral Hernia Repair
Status: Enrolling
Updated:  11/2/2017
Wake Forest University Health Sciences
mi
from
Winston-Salem, NC
Wound Healing of Incisional Wounds for Bilateral Hernia Repair
The Effect of a Sodium Bicarbonate and Hydrogen Peroxide Gel on Wound Healing of Incisional Wounds for Bilateral Hernia Repair
Status: Enrolling
Updated: 11/2/2017
Wake Forest University Health Sciences
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Drug-drug Interaction Study Between EDP-305, Intraconazole and Rifampin in Healthy Volunteers
A Non-Randomized, Open-Label, Two-Part, Drug-Drug Interaction Study to Evaluate the Effects of Itraconazole and Rifampin on the Pharmacokinetics and Safety of EDP-305 in Healthy Volunteers
Status: Enrolling
Updated:  11/2/2017
Pharmaceutical Research Associates, Inc.
mi
from
Lenexa, KA
Drug-drug Interaction Study Between EDP-305, Intraconazole and Rifampin in Healthy Volunteers
A Non-Randomized, Open-Label, Two-Part, Drug-Drug Interaction Study to Evaluate the Effects of Itraconazole and Rifampin on the Pharmacokinetics and Safety of EDP-305 in Healthy Volunteers
Status: Enrolling
Updated: 11/2/2017
Pharmaceutical Research Associates, Inc.
mi
from
Lenexa, KA
Click here to add this to my saved trials
Remote Observed Dosing to Increase Suboxone Compliance
Status: Enrolling
Updated:  11/3/2017
Univ of Pennsylvania
mi
from
Philadelphia, PA
Remote Observed Dosing to Increase Suboxone Compliance
Status: Enrolling
Updated: 11/3/2017
Univ of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Improvement of Pain Following Robotic Sacrocolpopexy and Rectocele Repair for Pelvic Organ Prolapse
Does Liposomal Bupivacaine Improve Pain Following Robotic Sacrocolpopexy and Rectocele Repair for Pelvic Organ Prolapse? A Randomized Placebo Controlled Trial
Status: Enrolling
Updated:  11/3/2017
Cincinnati Urogynecology Associates
mi
from
Cincinnati, OH
Improvement of Pain Following Robotic Sacrocolpopexy and Rectocele Repair for Pelvic Organ Prolapse
Does Liposomal Bupivacaine Improve Pain Following Robotic Sacrocolpopexy and Rectocele Repair for Pelvic Organ Prolapse? A Randomized Placebo Controlled Trial
Status: Enrolling
Updated: 11/3/2017
Cincinnati Urogynecology Associates
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Eval. of Potential Predictors of Disease Progression in Patients With aHUS Including Genetics, Biomarkers and Treatment
Evaluation of Potential Predictors of Disease Progression in Patients With aHUS, Including Genetics, Biomarkers and Treatment
Status: Enrolling
Updated:  11/3/2017
Clinical Trial Site
mi
from
Washington,
Eval. of Potential Predictors of Disease Progression in Patients With aHUS Including Genetics, Biomarkers and Treatment
Evaluation of Potential Predictors of Disease Progression in Patients With aHUS, Including Genetics, Biomarkers and Treatment
Status: Enrolling
Updated: 11/3/2017
Clinical Trial Site
mi
from
Washington,
Click here to add this to my saved trials
Eval. of Potential Predictors of Disease Progression in Patients With aHUS Including Genetics, Biomarkers and Treatment
Evaluation of Potential Predictors of Disease Progression in Patients With aHUS, Including Genetics, Biomarkers and Treatment
Status: Enrolling
Updated:  11/3/2017
Clinical Site
mi
from
Atlanta, GA
Eval. of Potential Predictors of Disease Progression in Patients With aHUS Including Genetics, Biomarkers and Treatment
Evaluation of Potential Predictors of Disease Progression in Patients With aHUS, Including Genetics, Biomarkers and Treatment
Status: Enrolling
Updated: 11/3/2017
Clinical Site
mi
from
Atlanta, GA
Click here to add this to my saved trials
Eval. of Potential Predictors of Disease Progression in Patients With aHUS Including Genetics, Biomarkers and Treatment
Evaluation of Potential Predictors of Disease Progression in Patients With aHUS, Including Genetics, Biomarkers and Treatment
Status: Enrolling
Updated:  11/3/2017
Clinical Site
mi
from
Chicago, IL
Eval. of Potential Predictors of Disease Progression in Patients With aHUS Including Genetics, Biomarkers and Treatment
Evaluation of Potential Predictors of Disease Progression in Patients With aHUS, Including Genetics, Biomarkers and Treatment
Status: Enrolling
Updated: 11/3/2017
Clinical Site
mi
from
Chicago, IL
Click here to add this to my saved trials
Eval. of Potential Predictors of Disease Progression in Patients With aHUS Including Genetics, Biomarkers and Treatment
Evaluation of Potential Predictors of Disease Progression in Patients With aHUS, Including Genetics, Biomarkers and Treatment
Status: Enrolling
Updated:  11/3/2017
Clinical Site
mi
from
Boston, MA
Eval. of Potential Predictors of Disease Progression in Patients With aHUS Including Genetics, Biomarkers and Treatment
Evaluation of Potential Predictors of Disease Progression in Patients With aHUS, Including Genetics, Biomarkers and Treatment
Status: Enrolling
Updated: 11/3/2017
Clinical Site
mi
from
Boston, MA
Click here to add this to my saved trials
Eval. of Potential Predictors of Disease Progression in Patients With aHUS Including Genetics, Biomarkers and Treatment
Evaluation of Potential Predictors of Disease Progression in Patients With aHUS, Including Genetics, Biomarkers and Treatment
Status: Enrolling
Updated:  11/3/2017
Clinical Trial Site
mi
from
Hackensack, NJ
Eval. of Potential Predictors of Disease Progression in Patients With aHUS Including Genetics, Biomarkers and Treatment
Evaluation of Potential Predictors of Disease Progression in Patients With aHUS, Including Genetics, Biomarkers and Treatment
Status: Enrolling
Updated: 11/3/2017
Clinical Trial Site
mi
from
Hackensack, NJ
Click here to add this to my saved trials
Eval. of Potential Predictors of Disease Progression in Patients With aHUS Including Genetics, Biomarkers and Treatment
Evaluation of Potential Predictors of Disease Progression in Patients With aHUS, Including Genetics, Biomarkers and Treatment
Status: Enrolling
Updated:  11/3/2017
Clinical Trial Site
mi
from
Columbus, OH
Eval. of Potential Predictors of Disease Progression in Patients With aHUS Including Genetics, Biomarkers and Treatment
Evaluation of Potential Predictors of Disease Progression in Patients With aHUS, Including Genetics, Biomarkers and Treatment
Status: Enrolling
Updated: 11/3/2017
Clinical Trial Site
mi
from
Columbus, OH
Click here to add this to my saved trials
Eval. of Potential Predictors of Disease Progression in Patients With aHUS Including Genetics, Biomarkers and Treatment
Evaluation of Potential Predictors of Disease Progression in Patients With aHUS, Including Genetics, Biomarkers and Treatment
Status: Enrolling
Updated:  11/3/2017
Clinical Trial Site
mi
from
Adelaide,
Eval. of Potential Predictors of Disease Progression in Patients With aHUS Including Genetics, Biomarkers and Treatment
Evaluation of Potential Predictors of Disease Progression in Patients With aHUS, Including Genetics, Biomarkers and Treatment
Status: Enrolling
Updated: 11/3/2017
Clinical Trial Site
mi
from
Adelaide,
Click here to add this to my saved trials
Eval. of Potential Predictors of Disease Progression in Patients With aHUS Including Genetics, Biomarkers and Treatment
Evaluation of Potential Predictors of Disease Progression in Patients With aHUS, Including Genetics, Biomarkers and Treatment
Status: Enrolling
Updated:  11/3/2017
Clinical Trial Site
mi
from
Charlotte, NC
Eval. of Potential Predictors of Disease Progression in Patients With aHUS Including Genetics, Biomarkers and Treatment
Evaluation of Potential Predictors of Disease Progression in Patients With aHUS, Including Genetics, Biomarkers and Treatment
Status: Enrolling
Updated: 11/3/2017
Clinical Trial Site
mi
from
Charlotte, NC
Click here to add this to my saved trials
Eval. of Potential Predictors of Disease Progression in Patients With aHUS Including Genetics, Biomarkers and Treatment
Evaluation of Potential Predictors of Disease Progression in Patients With aHUS, Including Genetics, Biomarkers and Treatment
Status: Enrolling
Updated:  11/3/2017
Clinical Trial Site
mi
from
Winston-Salem, NC
Eval. of Potential Predictors of Disease Progression in Patients With aHUS Including Genetics, Biomarkers and Treatment
Evaluation of Potential Predictors of Disease Progression in Patients With aHUS, Including Genetics, Biomarkers and Treatment
Status: Enrolling
Updated: 11/3/2017
Clinical Trial Site
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Eval. of Potential Predictors of Disease Progression in Patients With aHUS Including Genetics, Biomarkers and Treatment
Evaluation of Potential Predictors of Disease Progression in Patients With aHUS, Including Genetics, Biomarkers and Treatment
Status: Enrolling
Updated:  11/3/2017
Clinical Site
mi
from
Houston, TX
Eval. of Potential Predictors of Disease Progression in Patients With aHUS Including Genetics, Biomarkers and Treatment
Evaluation of Potential Predictors of Disease Progression in Patients With aHUS, Including Genetics, Biomarkers and Treatment
Status: Enrolling
Updated: 11/3/2017
Clinical Site
mi
from
Houston, TX
Click here to add this to my saved trials
Biospecimens for Identification of Diseases of the Pancreas.
Biospecimens for the Early Detection, Prevention, Diagnosis and Treatment of Diseases of the Pancreas.
Status: Enrolling
Updated:  11/6/2017
Univerisity of Michigan
mi
from
Ann Arbor, MI
Biospecimens for Identification of Diseases of the Pancreas.
Biospecimens for the Early Detection, Prevention, Diagnosis and Treatment of Diseases of the Pancreas.
Status: Enrolling
Updated: 11/6/2017
Univerisity of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Relationship Between HbA1c and Chronic Glycemia in Patients With Cirrhosis
Relationship Between HbA1c and Chronic Glycemia in Patients With Cirrhosis: a Pilot Study to Better Characterize and Standardize the Test
Status: Enrolling
Updated:  11/6/2017
University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
Relationship Between HbA1c and Chronic Glycemia in Patients With Cirrhosis
Relationship Between HbA1c and Chronic Glycemia in Patients With Cirrhosis: a Pilot Study to Better Characterize and Standardize the Test
Status: Enrolling
Updated: 11/6/2017
University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
Click here to add this to my saved trials
Correlation of Hepatitis C, Alcoholic Liver Disease, and Renal Failure With Hyperfibrinolysis in Liver Failure
Status: Enrolling
Updated:  11/6/2017
University of Utah
mi
from
Salt Lake City, UT
Correlation of Hepatitis C, Alcoholic Liver Disease, and Renal Failure With Hyperfibrinolysis in Liver Failure
Status: Enrolling
Updated: 11/6/2017
University of Utah
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
19 Versus 22-Gauge Needle for EUS-LB
19 Versus 22-Gauge Fine Needle Biopsy (FNB) Needles for Endoscopic Ultrasound Guided Liver Biopsy (EUS-LB): A Prospective Pilot Study
Status: Enrolling
Updated:  11/7/2017
Geisinger Medical Center
mi
from
Danville, PA
19 Versus 22-Gauge Needle for EUS-LB
19 Versus 22-Gauge Fine Needle Biopsy (FNB) Needles for Endoscopic Ultrasound Guided Liver Biopsy (EUS-LB): A Prospective Pilot Study
Status: Enrolling
Updated: 11/7/2017
Geisinger Medical Center
mi
from
Danville, PA
Click here to add this to my saved trials
A Study to Evaluate the Effect of Camicinal on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
A Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Effect of 12 Weeks of Once-daily Dosing of the Oral Motilin Receptor Agonist Camicinal, on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
Status: Enrolling
Updated:  11/8/2017
GSK Investigational Site
mi
from
Chandler, AZ
A Study to Evaluate the Effect of Camicinal on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
A Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Effect of 12 Weeks of Once-daily Dosing of the Oral Motilin Receptor Agonist Camicinal, on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
Status: Enrolling
Updated: 11/8/2017
GSK Investigational Site
mi
from
Chandler, AZ
Click here to add this to my saved trials
A Study to Evaluate the Effect of Camicinal on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
A Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Effect of 12 Weeks of Once-daily Dosing of the Oral Motilin Receptor Agonist Camicinal, on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
Status: Enrolling
Updated:  11/8/2017
GSK Investigational Site
mi
from
Long Beach, CA
A Study to Evaluate the Effect of Camicinal on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
A Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Effect of 12 Weeks of Once-daily Dosing of the Oral Motilin Receptor Agonist Camicinal, on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
Status: Enrolling
Updated: 11/8/2017
GSK Investigational Site
mi
from
Long Beach, CA
Click here to add this to my saved trials
A Study to Evaluate the Effect of Camicinal on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
A Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Effect of 12 Weeks of Once-daily Dosing of the Oral Motilin Receptor Agonist Camicinal, on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
Status: Enrolling
Updated:  11/8/2017
GSK Investigational Site
mi
from
Northridge, CA
A Study to Evaluate the Effect of Camicinal on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
A Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Effect of 12 Weeks of Once-daily Dosing of the Oral Motilin Receptor Agonist Camicinal, on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
Status: Enrolling
Updated: 11/8/2017
GSK Investigational Site
mi
from
Northridge, CA
Click here to add this to my saved trials
A Study to Evaluate the Effect of Camicinal on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
A Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Effect of 12 Weeks of Once-daily Dosing of the Oral Motilin Receptor Agonist Camicinal, on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
Status: Enrolling
Updated:  11/8/2017
GSK Investigational Site
mi
from
Hialeah, FL
A Study to Evaluate the Effect of Camicinal on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
A Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Effect of 12 Weeks of Once-daily Dosing of the Oral Motilin Receptor Agonist Camicinal, on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
Status: Enrolling
Updated: 11/8/2017
GSK Investigational Site
mi
from
Hialeah, FL
Click here to add this to my saved trials
A Study to Evaluate the Effect of Camicinal on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
A Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Effect of 12 Weeks of Once-daily Dosing of the Oral Motilin Receptor Agonist Camicinal, on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
Status: Enrolling
Updated:  11/8/2017
GSK Investigational Site
mi
from
Inverness, FL
A Study to Evaluate the Effect of Camicinal on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
A Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Effect of 12 Weeks of Once-daily Dosing of the Oral Motilin Receptor Agonist Camicinal, on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
Status: Enrolling
Updated: 11/8/2017
GSK Investigational Site
mi
from
Inverness, FL
Click here to add this to my saved trials
A Study to Evaluate the Effect of Camicinal on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
A Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Effect of 12 Weeks of Once-daily Dosing of the Oral Motilin Receptor Agonist Camicinal, on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
Status: Enrolling
Updated:  11/8/2017
GSK Investigational Site
mi
from
Miami, FL
A Study to Evaluate the Effect of Camicinal on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
A Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Effect of 12 Weeks of Once-daily Dosing of the Oral Motilin Receptor Agonist Camicinal, on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
Status: Enrolling
Updated: 11/8/2017
GSK Investigational Site
mi
from
Miami, FL
Click here to add this to my saved trials
A Study to Evaluate the Effect of Camicinal on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
A Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Effect of 12 Weeks of Once-daily Dosing of the Oral Motilin Receptor Agonist Camicinal, on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
Status: Enrolling
Updated:  11/8/2017
GSK Investigational Site
mi
from
Port Orange, FL
A Study to Evaluate the Effect of Camicinal on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
A Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Effect of 12 Weeks of Once-daily Dosing of the Oral Motilin Receptor Agonist Camicinal, on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
Status: Enrolling
Updated: 11/8/2017
GSK Investigational Site
mi
from
Port Orange, FL
Click here to add this to my saved trials
A Study to Evaluate the Effect of Camicinal on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
A Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Effect of 12 Weeks of Once-daily Dosing of the Oral Motilin Receptor Agonist Camicinal, on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
Status: Enrolling
Updated:  11/8/2017
GSK Investigational Site
mi
from
Atlanta, GA
A Study to Evaluate the Effect of Camicinal on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
A Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Effect of 12 Weeks of Once-daily Dosing of the Oral Motilin Receptor Agonist Camicinal, on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
Status: Enrolling
Updated: 11/8/2017
GSK Investigational Site
mi
from
Atlanta, GA
Click here to add this to my saved trials
A Study to Evaluate the Effect of Camicinal on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
A Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Effect of 12 Weeks of Once-daily Dosing of the Oral Motilin Receptor Agonist Camicinal, on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
Status: Enrolling
Updated:  11/8/2017
GSK Investigational Site
mi
from
Marietta, GA
A Study to Evaluate the Effect of Camicinal on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
A Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Effect of 12 Weeks of Once-daily Dosing of the Oral Motilin Receptor Agonist Camicinal, on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
Status: Enrolling
Updated: 11/8/2017
GSK Investigational Site
mi
from
Marietta, GA
Click here to add this to my saved trials
A Study to Evaluate the Effect of Camicinal on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
A Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Effect of 12 Weeks of Once-daily Dosing of the Oral Motilin Receptor Agonist Camicinal, on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
Status: Enrolling
Updated:  11/8/2017
GSK Investigational Site
mi
from
Indianapolis, IN
A Study to Evaluate the Effect of Camicinal on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
A Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Effect of 12 Weeks of Once-daily Dosing of the Oral Motilin Receptor Agonist Camicinal, on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
Status: Enrolling
Updated: 11/8/2017
GSK Investigational Site
mi
from
Indianapolis, IN
Click here to add this to my saved trials
A Study to Evaluate the Effect of Camicinal on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
A Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Effect of 12 Weeks of Once-daily Dosing of the Oral Motilin Receptor Agonist Camicinal, on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
Status: Enrolling
Updated:  11/8/2017
GSK Investigational Site
mi
from
Towson, MD
A Study to Evaluate the Effect of Camicinal on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
A Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Effect of 12 Weeks of Once-daily Dosing of the Oral Motilin Receptor Agonist Camicinal, on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
Status: Enrolling
Updated: 11/8/2017
GSK Investigational Site
mi
from
Towson, MD
Click here to add this to my saved trials
A Study to Evaluate the Effect of Camicinal on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
A Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Effect of 12 Weeks of Once-daily Dosing of the Oral Motilin Receptor Agonist Camicinal, on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
Status: Enrolling
Updated:  11/8/2017
GSK Investigational Site
mi
from
Boston, MA
A Study to Evaluate the Effect of Camicinal on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
A Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Effect of 12 Weeks of Once-daily Dosing of the Oral Motilin Receptor Agonist Camicinal, on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
Status: Enrolling
Updated: 11/8/2017
GSK Investigational Site
mi
from
Boston, MA
Click here to add this to my saved trials
A Study to Evaluate the Effect of Camicinal on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
A Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Effect of 12 Weeks of Once-daily Dosing of the Oral Motilin Receptor Agonist Camicinal, on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
Status: Enrolling
Updated:  11/8/2017
GSK Investigational Site
mi
from
Boston, MA
A Study to Evaluate the Effect of Camicinal on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
A Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Effect of 12 Weeks of Once-daily Dosing of the Oral Motilin Receptor Agonist Camicinal, on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
Status: Enrolling
Updated: 11/8/2017
GSK Investigational Site
mi
from
Boston, MA
Click here to add this to my saved trials
A Study to Evaluate the Effect of Camicinal on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
A Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Effect of 12 Weeks of Once-daily Dosing of the Oral Motilin Receptor Agonist Camicinal, on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
Status: Enrolling
Updated:  11/8/2017
GSK Investigational Site
mi
from
Flint, MI
A Study to Evaluate the Effect of Camicinal on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
A Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Effect of 12 Weeks of Once-daily Dosing of the Oral Motilin Receptor Agonist Camicinal, on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
Status: Enrolling
Updated: 11/8/2017
GSK Investigational Site
mi
from
Flint, MI
Click here to add this to my saved trials
A Study to Evaluate the Effect of Camicinal on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
A Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Effect of 12 Weeks of Once-daily Dosing of the Oral Motilin Receptor Agonist Camicinal, on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
Status: Enrolling
Updated:  11/8/2017
GSK Investigational Site
mi
from
Wyoming, MI
A Study to Evaluate the Effect of Camicinal on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
A Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Effect of 12 Weeks of Once-daily Dosing of the Oral Motilin Receptor Agonist Camicinal, on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
Status: Enrolling
Updated: 11/8/2017
GSK Investigational Site
mi
from
Wyoming, MI
Click here to add this to my saved trials
A Study to Evaluate the Effect of Camicinal on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
A Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Effect of 12 Weeks of Once-daily Dosing of the Oral Motilin Receptor Agonist Camicinal, on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
Status: Enrolling
Updated:  11/8/2017
GSK Investigational Site
mi
from
Las Vegas, NV
A Study to Evaluate the Effect of Camicinal on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
A Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Effect of 12 Weeks of Once-daily Dosing of the Oral Motilin Receptor Agonist Camicinal, on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
Status: Enrolling
Updated: 11/8/2017
GSK Investigational Site
mi
from
Las Vegas, NV
Click here to add this to my saved trials
A Study to Evaluate the Effect of Camicinal on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
A Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Effect of 12 Weeks of Once-daily Dosing of the Oral Motilin Receptor Agonist Camicinal, on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
Status: Enrolling
Updated:  11/8/2017
GSK Investigational Site
mi
from
Las Vegas, NV
A Study to Evaluate the Effect of Camicinal on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
A Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Effect of 12 Weeks of Once-daily Dosing of the Oral Motilin Receptor Agonist Camicinal, on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
Status: Enrolling
Updated: 11/8/2017
GSK Investigational Site
mi
from
Las Vegas, NV
Click here to add this to my saved trials
A Study to Evaluate the Effect of Camicinal on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
A Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Effect of 12 Weeks of Once-daily Dosing of the Oral Motilin Receptor Agonist Camicinal, on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
Status: Enrolling
Updated:  11/8/2017
GSK Investigational Site
mi
from
Albuquerque, NM
A Study to Evaluate the Effect of Camicinal on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
A Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Effect of 12 Weeks of Once-daily Dosing of the Oral Motilin Receptor Agonist Camicinal, on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
Status: Enrolling
Updated: 11/8/2017
GSK Investigational Site
mi
from
Albuquerque, NM
Click here to add this to my saved trials
A Study to Evaluate the Effect of Camicinal on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
A Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Effect of 12 Weeks of Once-daily Dosing of the Oral Motilin Receptor Agonist Camicinal, on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
Status: Enrolling
Updated:  11/8/2017
GSK Investigational Site
mi
from
Poughkeepsie, NY
A Study to Evaluate the Effect of Camicinal on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
A Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Effect of 12 Weeks of Once-daily Dosing of the Oral Motilin Receptor Agonist Camicinal, on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
Status: Enrolling
Updated: 11/8/2017
GSK Investigational Site
mi
from
Poughkeepsie, NY
Click here to add this to my saved trials
A Study to Evaluate the Effect of Camicinal on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
A Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Effect of 12 Weeks of Once-daily Dosing of the Oral Motilin Receptor Agonist Camicinal, on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
Status: Enrolling
Updated:  11/8/2017
GSK Investigational Site
mi
from
Greensboro, NC
A Study to Evaluate the Effect of Camicinal on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
A Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Effect of 12 Weeks of Once-daily Dosing of the Oral Motilin Receptor Agonist Camicinal, on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
Status: Enrolling
Updated: 11/8/2017
GSK Investigational Site
mi
from
Greensboro, NC
Click here to add this to my saved trials
A Study to Evaluate the Effect of Camicinal on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
A Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Effect of 12 Weeks of Once-daily Dosing of the Oral Motilin Receptor Agonist Camicinal, on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
Status: Enrolling
Updated:  11/8/2017
GSK Investigational Site
mi
from
Winston-Salem, NC
A Study to Evaluate the Effect of Camicinal on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
A Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Effect of 12 Weeks of Once-daily Dosing of the Oral Motilin Receptor Agonist Camicinal, on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
Status: Enrolling
Updated: 11/8/2017
GSK Investigational Site
mi
from
Winston-Salem, NC
Click here to add this to my saved trials